|
110 Companies |
|
139 Products |
|
139 Products |
|
95 Mechanisms of Action |
|
2 Trials |
|
919 News |
|
| «12...4567891011121314...1819» |
- Clinical: Effect of Exercise and Diet on Psoriatic Arthritis (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=55, Completed, Sponsor: Faculty of Medicine, University of Alexandria
- ||| Enrollment closed: Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis (clinicaltrials.gov) - Jul 12, 2014
P2, N=92, Active, not recruiting, Sponsor: AmDerma
Recruiting --> Active, not recruiting
- | Trial completion, Trial primary completion date: Immune Signature of Palmoplantar Pustulosis (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=30, Completed, Sponsor: Baylor Research Institute
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jul 2014
- |||||| Cosentyx (secukinumab) / Novartis
Enrollment open, Trial initiation date: CLEAR: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis (clinicaltrials.gov) - Jul 12, 2014
P3, N=640, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jul 2014 Active, not recruiting --> Recruiting | Initiation date: Apr 2013 --> May 2011
- | Dovonex (calcipotriol) / LEO Pharma, Novartis
Trial completion, Trial primary completion date: SHP-141C in Plaque Type Psoriasis (clinicaltrials.gov) - Jul 12, 2014
P1, N=14, Completed, Sponsor: TetraLogic Pharmaceuticals
Active, not recruiting --> Recruiting | Initiation date: Apr 2013 --> May 2011 Active, not recruiting --> Completed | Trial primary completion date: Feb 2013 --> Nov 2012
- Prurisol (abacavir gylcolate) / Innovation Pharma
Enrollment closed: Bioequivalence and Pharmacokinetic Study of Prurisol (clinicaltrials.gov) - Jul 10, 2014
P1, N=18, Active, not recruiting, Sponsor: Cellceutix Corporation
Active, not recruiting --> Completed | Trial primary completion date: Feb 2013 --> Nov 2012 Recruiting --> Active, not recruiting
- |||||||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
New P3 trial: A Study of Golimumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - Jul 8, 2014
P3, N=440, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Enrollment closed: SPIRIT-P1: A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - Jul 8, 2014
P3, N=412, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- bexarotene/betamethasone dipropionate (LAS 41004) / Almirall
New P2a trial: Left/Right: A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis (clinicaltrials.gov) - Jul 2, 2014
P2a, N=40, Recruiting, Sponsor: Almirall, S.A.
- ||| Trial completion, HEOR: Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=1000, Completed, Sponsor: Jochen Schmitt.
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- Pandel (hydrocortisone probutate) / Novartis
Trial primary completion date: Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population (clinicaltrials.gov) - Jun 27, 2014
P4, N=19, Suspended, Sponsor: Fougera Pharmaceuticals Inc.
Not yet recruiting --> Completed Trial primary completion date: Dec 2011 --> Dec 2014
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial primary completion date: Golimumab Plus UVB-311nm in Psoriasis (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=20, Terminated, Sponsor: Medical University of Graz
Trial primary completion date: Dec 2011 --> Dec 2014 Trial primary completion date: Dec 2014 --> Oct 2010
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial termination, Trial primary completion date: Golimumab Plus UVB-311nm in Psoriasis (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=20, Terminated, Sponsor: Medical University of Graz
Trial primary completion date: Dec 2014 --> Oct 2010 Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Oct 2010; Difficulties in recruiting patients;
- ||| Xeljanz (tofacitinib) / Pfizer
Clinical: Tofacitinib Ointment For Chronic Plaque Psoriasis (clinicaltrials.gov) - Jun 27, 2014
P2, N=480, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Oct 2010; Difficulties in recruiting patients; Recruiting --> Active, not recruiting
- Stelara (ustekinumab) / J&J
Trial primary completion date, HEOR: The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment (clinicaltrials.gov) - Jun 22, 2014
P4, N=35, Recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2013 --> Dec 2014
- |||||| Cosentyx (secukinumab) / Novartis
Enrollment open: FUTURE 3: 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis (clinicaltrials.gov) - Jun 19, 2014
P3, N=405, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2013 --> Dec 2014 Not yet recruiting --> Recruiting
- | tacrolimus topical / Generic mfg.
Enrollment open: Tacrolimus Ointment Interest (PROTOPIC (clinicaltrials.gov) - Jun 19, 2014
P3, N=240, Recruiting, Sponsor: University Hospital, Rouen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| Cosentyx (secukinumab) / Novartis
Enrollment open: GESTURE: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (clinicaltrials.gov) - Jun 19, 2014
P3, N=201, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||||| Cosentyx (secukinumab) / Novartis
Enrollment closed: CLEAR: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis (clinicaltrials.gov) - Jun 19, 2014
P3, N=640, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Enbrel (etanercept) / Pfizer, Amgen
New P3 trial: Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? (clinicaltrials.gov) - Jun 17, 2014
P3, N=60, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
- ||| VB-201 / VBL Therap
Enrollment closed: A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis (clinicaltrials.gov) - Jun 13, 2014
P2, N=194, Active, not recruiting, Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Cosentyx (secukinumab) / Novartis
Trial primary completion date: Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab (clinicaltrials.gov) - Jun 12, 2014
P3, N=1144, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2015 --> Jun 2017
- |||||||||| tazarotene topical / Generic mfg.
New P3 trial: Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis (clinicaltrials.gov) - Jun 12, 2014
P3, N=804, Recruiting, Sponsor: G & W Laboratories Inc.
- ||||| Cosentyx (secukinumab) / Novartis
P3 data, Trial initiation date: 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis (clinicaltrials.gov) - Jun 8, 2014
P3, N=740, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2015 --> Jun 2017 Initiation date: Sep 2012 --> Jan 2012
- bexarotene/betamethasone dipropionate (LAS 41004) / Almirall
Trial completion: Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test (clinicaltrials.gov) - Jun 5, 2014
P1/2, N=18, Completed, Sponsor: Almirall, S.A.
Initiation date: Sep 2012 --> Jan 2012 Recruiting --> Completed
- | Cosentyx (secukinumab) / Novartis
Enrollment change: Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) (clinicaltrials.gov) - Jun 4, 2014
P3, N=12, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed N=10 --> 12
- | Cosentyx (secukinumab) / Novartis
Enrollment closed: Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) (clinicaltrials.gov) - Jun 4, 2014
P3, N=12, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=10 --> 12 Recruiting --> Active, not recruiting
- ||||| Cosentyx (secukinumab) / Novartis
Enrollment closed, P3 data: 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis (clinicaltrials.gov) - Jun 4, 2014
P3, N=740, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Cosentyx (secukinumab) / Novartis
Trial initiation date: CLEAR: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis (clinicaltrials.gov) - Jun 4, 2014
P3, N=640, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Initiation date: Feb 2014 --> Apr 2013
- Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Enrollment closed: Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects (clinicaltrials.gov) - Jun 4, 2014
P1, N=30, Active, not recruiting, Sponsor: Amgen
Initiation date: Feb 2014 --> Apr 2013 Recruiting --> Active, not recruiting
- | sonelokimab (M1095) / Avillion, MoonLake Immunotherap
New P1 trial: Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects (clinicaltrials.gov) - Jun 3, 2014
P1, N=40, Not yet recruiting, Sponsor: Merck KGaA
- Cosentyx (secukinumab) / Novartis
Trial primary completion date: Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) (clinicaltrials.gov) - Jun 2, 2014
P3, N=10, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2015 --> Jan 2017
- ||| Clinical: An Exploratory Genetic Study in Participants With Psoriasis (clinicaltrials.gov) - Jun 2, 2014
P0, N=250, Recruiting, Sponsor: Janssen Research & Development, LLC
- calcipotriol/betamethasone dipropionate / Generic mfg.
Trial completion: TRIANGLE: Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris (clinicaltrials.gov) - Jun 2, 2014
P4, N=201, Completed, Sponsor: Jooheung Lee
Trial primary completion date: Nov 2015 --> Jan 2017 Active, not recruiting --> Completed
- Clinical: Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=384, Recruiting, Sponsor: Guangdong Provincial Hospital of Traditional Chinese Medicine
- | Trial completion: Blue Light for Treating Psoriasis Vulgaris (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=47, Completed, Sponsor: Light and Health Venture
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, HEOR, Real-world evidence, Real-world: Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=152, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Clinical: Impact of Continuous Defocused CO2 Laser Vaporisation on the Histological Malignant Transformation of Erosive Oral Lichen Planus in Patients (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=263, Completed, Sponsor: Technische Universität München
- ||| Humira (adalimumab) / AbbVie
Trial completion: Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=566, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Premature Coronary Artery Disease (CAD) in Severe Psoriasis (clinicaltrials.gov) - May 29, 2014
P1, N=120, Active, not recruiting, Sponsor: University of Michigan
Active, not recruiting --> Completed Trial primary completion date: Oct 2013 --> Oct 2014
- Enrollment closed: Premature Coronary Artery Disease (CAD) in Severe Psoriasis (clinicaltrials.gov) - May 29, 2014
P1, N=120, Active, not recruiting, Sponsor: University of Michigan
Trial primary completion date: Oct 2013 --> Oct 2014 Recruiting --> Active, not recruiting
- || Trial primary completion date: Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents (clinicaltrials.gov) - May 29, 2014
P=N/A, N=90, Recruiting, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2013 --> Jul 2014
- |||| solcitinib (GSK2586184) / Galapagos
Trial completion: A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis (clinicaltrials.gov) - May 28, 2014
P2, N=68, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2013 --> Jul 2014 Active, not recruiting --> Completed
- |||||| Cosentyx (secukinumab) / Novartis
Enrollment open: TRANSFIGURE: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (clinicaltrials.gov) - May 28, 2014
P3, N=195, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Trial primary completion date: Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis (clinicaltrials.gov) - May 27, 2014
P1, N=39, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Recruiting Trial primary completion date: Oct 2013 --> May 2014
- | Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Trial completion: Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis (clinicaltrials.gov) - May 27, 2014
P1, N=39, Completed, Sponsor: Boehringer Ingelheim
Trial primary completion date: Oct 2013 --> May 2014 Active, not recruiting --> Completed
- Trial completion date: Prevalence of Sleep Disturbances in Psoriasis (clinicaltrials.gov) - May 26, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Wake Forest School of Medicine
Active, not recruiting --> Completed Trial completion date: Oct 2013 --> Oct 2014
- | New P4 trial: The NOR-SWITCH Study (clinicaltrials.gov) - May 26, 2014
P4, N=500, Not yet recruiting, Sponsor: Diakonhjemmet Hospital
- ||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment closed: Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - May 20, 2014
P2a, N=140, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Trial completion date: Oct 2013 --> Oct 2014 Recruiting --> Active, not recruiting
- || Enbrel (etanercept) / Pfizer, Amgen
Trial primary completion date: Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept (clinicaltrials.gov) - May 20, 2014
P4, N=217, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: May 2014 --> Mar 2014